The clinicopathologic features of YWHAE-FAM22 endometrial stromal sarcomas: A histologically high-grade and clinically aggressive tumor

American Journal of Surgical Pathology

Volumn 36, Issue 5, 2012, Pages 641-653

  Lee, Cheng Han ^a,c   Mariño Enriquez, Adrian ^a   Ou, Wenbin ^a   Zhu, Meijun ^a   Ali, Rola H ^c   Chiang, Sarah ^b   Amant, Frédéric ^d   Gilks, C Blake ^c   Van De Rijn, Matt ^e   Oliva, Esther ^b   Debiec Rychter, Maria ^d   Cin, Paola Dal ^a   Fletcher, Jonathan A ^a   Nucci, Marisa R ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c VANCOUVER GENERAL HOSPITAL   (Canada)

^d UNIVERSITY OF LEUVEN   (Belgium)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

14 3 3; endometrial stromal sarcoma; FAM22; JAZF1; YWHAE

Indexed keywords

JAZF1 PROTEIN, HUMAN; PROTEIN 14 3 3; TUMOR MARKER; TUMOR PROTEIN; YWHAE PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER STAGING; COMPARATIVE STUDY; ENDOMETRIUM SARCOMA; ENDOMETRIUM TUMOR; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLOW UP; GENETIC MARKER; GENETICS; HUMAN; KARYOTYPE; METABOLISM; MIDDLE AGED; MORTALITY; PATHOLOGY;

14-3-3 PROTEINS; ADULT; AGED; ENDOMETRIAL NEOPLASMS; FEMALE; FOLLOW-UP STUDIES; GENETIC MARKERS; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; KARYOTYPE; MIDDLE AGED; NEOPLASM PROTEINS; NEOPLASM STAGING; SARCOMA, ENDOMETRIAL STROMAL; TUMOR MARKERS, BIOLOGICAL;

EID: 84862789606     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0b013e31824a7b1a     Document Type: Article

References (41)

1. Abeler VM, Nenodovic M. Diagnostic immunohistochemistry in uterine sarcomas: a study of 397 cases. Int J Gynecol Pathol. 2011;30:236-243.
2. Abeler VM, Royne O, Thoresen S, et al. Uterine sarcomas in Norway. A histopathological and prognostic survey of a total population from 1970 to 2000 including 419 patients. Histopathology. 2009;54:355-364.
3. Amant F, Tousseyn T, Coenegrachts L, et al. Case report of a poorly differentiated uterine tumour with t(10;17) translocation andneuroectodermal phenotype. Anticancer Res. 2011;31:2367-2371.
4. Amant F, Woestenborghs H, Vandenbroucke V, et al. Transition of endometrial stromal sarcoma into high-grade sarcoma. Gynecol Oncol. 2006;103:1137-1140. (Pubitemid 44821342)
5. Bartosch C, Exposito MI, Lopes JM. Low-grade endometrial stromal sarcoma and undifferentiated endometrial sarcoma: a comparative analysis emphasizing the importance of distinguishing between these two groups. Int J Surg Pathol. 2010;18:286-291.
6. Brownlee NA, Perkins LA, Stewart W, et al. Recurring translocation (10;17) and deletion (14q) in clear cell sarcoma of the kidney. Arch Pathol Lab Med. 2007;131:446-451. (Pubitemid 46365527)
7. Chan JK, Kawar NM, Shin JY, et al. Endometrial stromal sarcoma: a population-based analysis. Br J Cancer. 2008;99:1210-1215.
8. Chang KL, Crabtree GS, Lim-Tan SK, et al. Primary uterine endometrial stromal neoplasms. A clinicopathologic study of 117 cases. Am J Surg Pathol. 1990;14:415-438. (Pubitemid 20140662)
9. Chew I, Oliva E. Endometrial stromal sarcomas: a review of potential prognostic factors. Adv Anat Pathol. 2010;17:113-121.
10. Chiang S, Ali R, Melnyk N, et al. Frequency of known gene rearrangements in endometrial stromal tumors. Am J Surg Pathol. 2011;35:1364-1372.
11. D'Angelo E, Spagnoli LG, Prat J. Comparative clinicopathologic and immunohistochemical analysis of uterine sarcomas diagnosedusing the World Health Organization classification system. Hum Pathol. 2009;40:1571-1585.
12. Denschlag D, Masoud I, Stanimir G, et al. Prognostic factors and outcome in women with uterine sarcoma. Eur J Surg Oncol. 2007;33:91-95. (Pubitemid 46156623)
13. Garg G, Shah JP, Toy EP, et al. Stage IA vs. IB endometrial stromal sarcoma: does the new staging system predict survival? Gynecol Oncol. 2010;118:8-13.
14. Hendrickson MR, Tavassoli FA, Kempson RL. Mesenchymal tumours and related lesions. In: Tavassoli FA, Devilee P. eds. World Health Organization Classification of Tumours Pathology andGenetics of Tumours of the Breast and Female Genital Organ. Lyon, France: IARC Press; 2003:233-236.
15. Hrzenjak A, Moinfar F, Tavassoli FA, et al. JAZF1/JJAZ1 gene fusion in endometrial stromal sarcomas: molecularanalysis by reverse transcriptase- polymerase chain reaction optimized for paraffin-embedded tissue. J Mol Diagn. 2005;7: 388-395. (Pubitemid 41149654)
16. Huang HY, Ladanyi M, Soslow RA. Molecular detection of JAZF1-JJAZ1 gene fusion in endometrial stromal neoplasms with classic and variant histology: evidence for genetic heterogeneity. Am J Surg Pathol. 2004;28:224-232. (Pubitemid 38124731)
17. Jung CK, Jung JH, Lee A, et al. Diagnostic use of nuclear betacatenin expression for the assessment of endometrial stromal tumors. Mod Pathol. 2008;21:756-763. (Pubitemid 351744843)
18. Knezevich SR, McFadden DE, Tao W, et al. A novel ETV6- NTRK3 gene fusion in congenital fibrosarcoma. Nat Genet. 1998;18:184-187. (Pubitemid 28082471)
19. Koontz JI, Soreng AL, Nucci M, et al. Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA. 2001;98:6348-6353. (Pubitemid 32488241)
20. Kurihara S, Oda Y, Ohishi Y, et al. Endometrial stromal sarcomas and related high-grade sarcomas: immunohistochemical and molecular genetic study of 31 cases. Am J Surg Pathol. 2008;32: 1228-1238.
21. Lamant L, Dastugue N, Pulford K, et al. A new fusion gene TPM3- ALK in anaplastic large cell lymphoma created by a (1;2)(q25;p23) translocation. Blood. 1999;93:3088-3095. (Pubitemid 29200802)
22. Lawrence B, Perez-Atayde A, Hibbard MK, et al. TPM3-ALK and TPM4-ALK oncogenes in inflammatory myofibroblastic tumors. Am J Pathol. 2000;157:377-384. (Pubitemid 30627557)
23. Lee CH, Ou WB, Mariño-Enriquez A, et al. 14-3-3 fusion oncogene in high-grade endometrial stromal sarcoma. Proc Natl Acad Sci USA. 2012;109:929-934.
24. Leunen K, Amant F, Debiec-Rychter M, et al. Endometrial stromal sarcoma presenting as postpartum haemorrhage: report of a case with a sole t(10;17)(q22;p13) translocation. Gynecol Oncol. 2003; 91:265-271. (Pubitemid 37188623)
25. Liegl B, Kepten I, Le C, et al. Heterogeneity of kinase inhibitor resistance mechanisms in GIST. J Pathol. 2008;216:64-74.
26. McCluggage WG, Sumathi VP, Maxwell P. CD10 is a sensitive and diagnostically useful immunohistochemical marker of normalendometrial stroma and of endometrial stromal neoplasms. Histopathology. 2001;39:273-278. (Pubitemid 34279662)
27. Micci F, Panagopoulos I, Bjerkehagen B, et al. Consistent rearrangement of chromosomal band 6p21 with generation of fusion genes JAZF1/PHF1 and EPC1/PHF1 in endometrial stromal sarcoma. Cancer Res. 2006;66:107-112. (Pubitemid 43166015)
28. Micci F, Walter CU, Teixeira MR, et al. Cytogenetic and molecular genetic analyses of endometrial stromal sarcoma: nonrandominvolvement of chromosome arms 6p and 7p and confirmation of JAZF1/JJAZ1 gene fusion in t(7;17). Cancer Genet Cytogenet. 2003;144:119-124. (Pubitemid 36808958)
29. Nucci MR, Harburger D, Koontz J, et al. Molecular analysis of the JAZF1-JJAZ1 gene fusion by RT-PCR and fluorescence in situ hybridization in endometrial stromal neoplasms. Am J Surg Pathol. 2007;31:65-70. (Pubitemid 46036903)
30. Ohta Y, Suzuki T, Omatsu M, et al. Transition from low-grade endometrial stromal sarcoma to high-grade endometrial stromal sarcoma. Int J Gynecol Pathol. 2010;29:374-377.
31. Oliva E, Clement PB, Young RH. Endometrial stromal tumors: an update on a group of tumors with a protean phenotype. Adv AnatPathol. 2000;7:257-281.
32. Oliva E, de Leval L, Soslow RA, et al. High frequency of JAZF1- JJAZ1 gene fusion in endometrial stromal tumors with smoothmuscle differentiation by interphase FISH detection. Am J Surg Pathol. 2007;31:1277-1284. (Pubitemid 47207134)
33. Oliva E, Young RH, Clement PB, et al. Myxoid and fibrous endometrial stromal tumors of the uterus: a report of 10 cases. Int J Gynecol Pathol. 1999;18:310-319. (Pubitemid 29489051)
34. O'Meara E, Stack D, Lee CH, et al. Characterisation of the chromosomal translocation t(10;17)(q22;p13) in clear cell sarcomaof kidney. J Pathol. 2012. doi: 10.1002/path.3985. [Epub ahead of print].
35. Punnett HH, Halligan GE, Zaeri N, et al. Translocation 10;17 in clear cell sarcoma of the kidney. A first report. Cancer Genet Cytogenet. 1989;41:123-128. (Pubitemid 19248000)
36. Rakheja D, Weinberg AG, Tomlinson GE, et al. Translocation (10;17)(q22;p13): a recurring translocation in clear cell sarcoma of kidney. Cancer Genet Cytogenet. 2004;154:175-179. (Pubitemid 39345815)
37. Regauer S, Emberger W, Reich O, et al. Cytogenetic analyses of two new cases of endometrial stromal sarcoma-non-random reciprocal translocation t(10;17)(q22;p13) correlates with fibrous ESS. Histopathology. 2008;52:780-783. (Pubitemid 351600059)
38. Sandberg AA. The cytogenetics and molecular biology of endometrial stromal sarcoma. Cytogenet Genome Res. 2007;118:182-189. (Pubitemid 350125255)
39. Tognon C, Knezevich SR, Auntsman D, et al. Expression of the ETV6-NTRK3 gene fusion as a primary event in human secretory breast carcinoma. Cancer Cell. 2002;2:367-376. (Pubitemid 41039103)
40. Vera AA, Guadarrama MB. Endometrial stromal sarcoma: clinicopathological and immunophenotype study of 18 cases. AnnDiagn Pathol. 2011;15:312-317
41. Yilmaz A, Rush DS, Soslow RA. Endometrial stromal sarcomas with unusual histologic features: a report of 24 primary and metastatic tumors emphasizing fibroblastic and smooth muscle differentiation. Am J Surg Pathol. 2002;26:1142-1150 (Pubitemid 34969183)